Management of 70-Year-Old Female with CAC Score of 178
For this 70-year-old woman with a CAC score of 178, I recommend initiating low-dose aspirin (75-100 mg daily) for primary prevention, provided she does not have high bleeding risk factors. 1
Rationale for Aspirin Therapy
Your patient's CAC score of 178 places her in a category where aspirin provides net benefit. The most recent comprehensive guidelines 1 and supporting research 2 demonstrate that CAC ≥100 identifies patients where the number needed to treat (NNT) to prevent one cardiovascular event is substantially lower than the number needed to harm (NNH) from bleeding. Specifically:
This favorable risk-benefit ratio holds true even though she is 70 years old, which technically falls at the upper age limit of the 2019 ACC/AHA recommendations (40-70 years) 4.
Critical Bleeding Risk Assessment
Before prescribing aspirin, you must exclude high bleeding risk factors:
- Prior gastrointestinal bleeding
- Known bleeding disorder or severe liver disease
- Thrombocytopenia
- Concurrent anticoagulation or regular NSAID use
- Uncontrolled hypertension 4
If any of these are present, aspirin would cause net harm regardless of CAC score 5.
Comprehensive Management Beyond Aspirin
Statin Therapy
With CAC 100-400, she should be on moderate-to-high intensity statin therapy if not already prescribed 1. The CAC score confirms subclinical atherosclerosis requiring aggressive lipid management.
Blood Pressure Management
Optimize blood pressure control, targeting <130/80 mmHg given her documented atherosclerosis 1.
Lifestyle Modifications
- Smoking cessation if applicable
- Mediterranean diet pattern
- Regular aerobic exercise (150 minutes/week moderate intensity)
- Weight management if overweight 6
Important Caveats
The evidence supporting CAC-guided aspirin therapy comes primarily from observational studies and modeling analyses 2, 3, not randomized trials. However, the 2023 JACC guidelines 1 explicitly endorse this approach, stating that "patients with CAC ≥100 should receive consideration for aspirin therapy" and that "CAC score can identify subcohorts who may benefit from aspirin therapy" with net benefit regardless of traditional risk factors.
The recent ASPREE trial 4 showed harm in healthy elderly patients (≥65 years), but this included many low-risk individuals. Your patient's CAC score of 178 definitively places her in a higher-risk category where the calculus changes favorably toward aspirin benefit 5.
Practical Implementation
- Aspirin dose: 75-100 mg daily 1
- Timing: Can be taken any time of day with food to minimize GI upset
- Monitoring: Annual assessment for bleeding symptoms; no routine laboratory monitoring required
- Duration: Continue indefinitely unless bleeding complications develop or bleeding risk factors emerge
The presence of measurable coronary calcium fundamentally changes her from a "primary prevention" patient to one with documented atherosclerotic disease, justifying more aggressive preventive pharmacotherapy 1, 2.